


## **Amendments to the Claims**

Kindly amend the specification as follows:

1. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a CCR-2 antagonist.

2. (currently amended) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



wherein:

X is selected from the group consisting of:

$$-\text{O}-, -\text{NR}^{20}-, -\text{S}-, -\text{SO}-, -\text{SO}_2-, \text{ and } -\text{CR}^{21}\text{R}^{22}-, -\text{NSO}_2\text{R}^{20}-,$$

-NCOR<sup>20</sup>-, -NCO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>CO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>OCOR<sup>20</sup>-, -CO-,

where R<sup>20</sup> is selected from: hydrogen, C<sub>1-6</sub> alkyl, benzyl, phenyl,

C3-6 cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1</sub>-3alkyl, C<sub>1</sub>-3alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1</sub>-6 alkyl, and trifluoromethyl,

where R<sup>21</sup> and R<sup>22</sup> are independently selected from: hydrogen, hydroxy,

C<sub>1-6</sub> alkyl, -O-C<sub>1-6</sub>alkyl, benzyl, phenyl, C<sub>3-6</sub> cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1-6</sub> alkyl, and trifluoromethyl;

R<sup>1</sup> is selected from:

-C<sub>1-6</sub>alkyl, -C<sub>0-6</sub>alkyl-O-C<sub>1-6</sub>alkyl-, -C<sub>0-6</sub>alkyl-S-C<sub>1-6</sub>alkyl-,  
-(C<sub>0-6</sub>alkyl)-(C<sub>3-7</sub>cycloalkyl)-(C<sub>0-6</sub>alkyl), hydroxy, -CO<sub>2</sub>R<sup>20</sup>, heterocycle,  
-CN, -NR<sup>20</sup>R<sup>26</sup>-, -NSO<sub>2</sub>R<sup>20</sup>-, -NCOR<sup>20</sup>-, -NCO<sub>2</sub>R<sup>20</sup>-, -NCOR<sup>20</sup>-,  
-CR<sup>21</sup>CO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>OCOR<sup>20</sup>-, phenyl and pyridyl,

where R<sup>26</sup> is selected from: hydrogen, C<sub>1-6</sub> alkyl, benzyl, phenyl, C<sub>3-6</sub> cycloalkyl

where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1-6</sub> alkyl, and trifluoromethyl

where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents

where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) -O-C<sub>1-3</sub>alkyl,
- (d) trifluoromethyl,
- (f) C<sub>1-3</sub>alkyl,
- (g) -O-C<sub>1-3</sub>alkyl,
- (h) -CO<sub>2</sub>R<sup>20</sup>,
- (i) -SO<sub>2</sub>R<sup>20</sup>,
- (j) -NHCOCH<sub>3</sub>,
- (k) -NHSO<sub>2</sub>CH<sub>3</sub>,
- (l) -heterocycle,
- (m) =O,
- (n) -CN,

and where the phenyl and pyridyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy and trifluoromethyl;

R<sup>2</sup> is selected from:


- (a) hydrogen,
- (b) hydroxy,

- (c) halo,
- (d) C<sub>1-3</sub>alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
- (e) -NR<sup>20</sup>R<sup>26</sup>,
- (f) -CO<sub>2</sub>R<sup>20</sup>,
- (g) -CONR<sup>20</sup>R<sup>26</sup>,
- (h) -NR<sup>20</sup>COR<sup>21</sup>,
- (i) -OCONR<sup>20</sup>R<sup>26</sup>,
- (j) -NR<sup>20</sup>CONR<sup>20</sup>R<sup>26</sup>,
- (k) -heterocycle,
- (l) -CN,
- (m) -NR<sup>20</sup>-SO<sub>2</sub>-NR<sup>20</sup>R<sup>26</sup>,
- (n) -NR<sup>20</sup>-SO<sub>2</sub>-R<sup>26</sup>,
- (o) -SO<sub>2</sub>-NR<sup>20</sup>R<sup>26</sup>, and
- (p) =O, where R<sup>2</sup> is connected to the ring via a double bond;

R<sup>3</sup> is oxygen or is absent;

R<sup>3</sup> is selected from:

- (a) — hydrogen,
- (b) — hydroxy,
- (c) — halo,
- (d) — C<sub>1-6</sub>alkyl,
- (e) — O-C<sub>1-6</sub>alkyl,
- (f) — NR<sup>20</sup>R<sup>21</sup>,
- (g) — NR<sup>20</sup>CO<sub>2</sub>R<sup>21</sup>,
- (h) — NR<sup>20</sup>CONR<sup>20</sup>R<sup>21</sup>,
- (i) — NR<sup>20</sup>-SO<sub>2</sub>-NR<sup>20</sup>R<sup>21</sup>,
- (j) — NR<sup>20</sup>-SO<sub>2</sub>-R<sup>21</sup>,
- (k) — heterocycle,
- (l) — CN,
- (m) — CONR<sup>20</sup>R<sup>21</sup>,
- (n) — CO<sub>2</sub>R<sup>20</sup>,
- (o) — NO<sub>2</sub>,
- (p) — S-R<sup>20</sup>,
- (q) — SO-R<sup>20</sup>,
- (r) — SO<sub>2</sub>-R<sup>20</sup>, and



R<sup>4</sup> is selected from:

- (a) hydrogen,
- (b) C<sub>1-6</sub>alkyl,
- (c) trifluoromethyl,
- (d) trifluoromethoxy,
- (e) chloro,
- (f) fluoro,
- (g) bromo, and
- (h) phenyl;

R<sup>5</sup> is selected from:

- (a) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro and optionally substituted with hydroxyl,
- (b) -O-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (c) -CO-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (d) -S-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (e) -pyridyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C<sub>1-4</sub>alkyl, and CO<sub>2</sub>R<sup>20</sup>,
- (f) fluoro,
- (g) chloro,
- (h) bromo,
- (i) -C<sub>4-6</sub>cycloalkyl,
- (j) -O-C<sub>4-6</sub>cycloalkyl,
- (k) phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C<sub>1-4</sub>alkyl, and CO<sub>2</sub>R<sup>20</sup>,
- (l) -O-phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C<sub>1-4</sub>alkyl, and CO<sub>2</sub>R<sup>20</sup>,

- (m)  $-C_{3-6}$ cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (n)  $-O-C_{3-6}$ cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (o) -heterocycle,
- (p) -CN, and
- (q)  $-CO_2R^{20}$ ;

$R^6$  is selected from:

- (a) hydrogen,
- (b)  $C_{1-6}$ alkyl, and
- (c) trifluoromethyl
- (d) fluoro
- (e) chloro, and
- (f) bromo;

$R^7$  is selected from:

- (a) hydrogen, and
- (b)  $C_{1-6}$ alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy,  $-CO_2H$ ,  $-CO_2C_{1-6}$ alkyl, and  $-O-C_{1-3}$ alkyl;

$R^8$  is selected from:

- (a) hydrogen,
- (b)  $C_{1-6}$ alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro,  $C_{1-3}$ alkoxy, hydroxy,  $-CO_2R^{20}$ ,
- (c) fluoro,
- (d)  $-O-C_{1-3}$ alkyl, where alkyl may be unsubstituted or substituted with 1-3 fluoro, and
- (e)  $C_{3-6}$  cycloalkyl,
- (f)  $-O-C_{3-6}$ cycloalkyl,
- (g) hydroxy,
- (h)  $-CO_2R^{20}$ ,
- (i)  $-OCOR^{20}$ ,

or  $R^7$  and  $R^8$  may be joined together via a  $C_{2-4}$ alkyl or a  $C_{0-2}$ alkyl- $O-C_{1-3}$ alkyl chain to form a 5-7 membered ring;

R<sup>9</sup> is selected from:

- (a) hydrogen,
  - (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,
  - (c) CO<sub>2</sub>R<sup>20</sup>,
  - (d) hydroxy, and
  - (e) -O-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,
- or R<sup>8</sup> and R<sup>9</sup> may be joined together by a C<sub>1-4</sub>alkyl chain or a C<sub>0-3</sub>alkyl-O-C<sub>0-3</sub>alkyl chain to form a 3-6 membered ring;

R<sup>10</sup> is selected from:

- (a) hydrogen, and
- (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (c) fluoro,
- (d) -O-C<sub>3-6</sub>cycloalkyl, and
- (e) -O-C<sub>1-3</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,

or R<sup>8</sup> and R<sup>10</sup> may be joined together by a C<sub>2-3</sub>alkyl chain to form a 5-6 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and C<sub>1-3</sub>alkoxy,

or R<sup>8</sup> and R<sup>10</sup> may be joined together by a C<sub>1-2</sub>alkyl-O-C<sub>1-2</sub>alkyl chain to form a 6-8 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and C<sub>1-3</sub>alkoxy,

or R<sup>8</sup> and R<sup>10</sup> may be joined together by a -O-C<sub>1-2</sub>alkyl-O-chain to form a 6-7 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and C<sub>1-3</sub>alkoxy;


n is selected from 0, 1 and 2;

the dashed line represents the optional presence of a second bond to form a single or a double bond;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

3. (currently amended) The method according to A method of claim 2, wherein X is oxygen.

4. (currently amended) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



and

